Evaxion Biotech A/S (NASDAQ:EVAX) Rating Reiterated by HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $14.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 389.51% from the company’s current price.

Evaxion Biotech A/S Price Performance

EVAX stock opened at $2.86 on Thursday. Evaxion Biotech A/S has a fifty-two week low of $2.26 and a fifty-two week high of $13.82. The business has a 50-day moving average of $3.15 and a 200-day moving average of $3.82. The stock has a market capitalization of $15.47 million, a P/E ratio of -0.66 and a beta of -0.28.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Tuesday, May 28th. The company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter. Equities analysts expect that Evaxion Biotech A/S will post -0.1 EPS for the current year.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. LM Advisors LLC acquired a new position in Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 337,336 shares of the company’s stock, valued at approximately $231,000. LM Advisors LLC owned 8.90% of Evaxion Biotech A/S at the end of the most recent reporting period. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.